SLC5A2 and hydrops fetalis: In detail, clinical trials such as DAPA-HF, EMPEROR-Reduced, and EMPA-TROPISM have consistently shown that SGLT2 inhibitors reverse and improve adverse cardiac remodeling in patients with HFrEF and HFpEF [11,168,169,170], which could explain the observed cardiovascular benefits [8,9].